Egetis Therapeutics
5.37 SEK
+0.19 %
Less than 1K followers
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.19 %
+8.27 %
+0.56 %
+4.27 %
+7.94 %
+31.94 %
+4.27 %
-6.80 %
-61.19 %
Egetis Therapeutics is a pharmaceutical company focused on developing innovative treatments for rare diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business has a global presence and serves customers worldwide. Egetis Therapeutics was founded in 2006 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
2.28B SEK
Turnover
2.15M SEK
Revenue
62.4M
EBIT %
-544.71 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
29.4
2026
Interim report Q1'26
6.5
2026
General meeting '26
21.8
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.
Redeye: Egetis Therapeutics (Q4 review): US approval on the horizon
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
